BioSpace News Archive

Alto Neuroscience Inc. today announced Amit Etkin, M.D., Ph.D., founder and chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference taking place January 9-12, 2023 in San Francisco, CA.

Regeneron Pharmaceuticals (NASDAQ: REGN) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for Libtayo ® (cemiplimab) as monotherapy to treat patients with advanced or recurrent cervical cancer whose disease progressed after chemotherapy.

Lipogems today announces it has raised €12.5M (approx. $13.2M ) in growth capital in 2022 to support the recent FDA approved IDE Studies for a separate and specific indication in Knee Osteoarthritis (OA).

Accord Healthcare, Inc. is voluntarily recalling a single lot of Daptomycin for Injection 500 mg/vial, and Daptomycin for Injection 350 mg/vial product contained in cartons imprinted with lot # R2200232 Exp: 01/2025 to the consumer/user level.

HTG Molecular Diagnostics, Inc. announced the closing of its previously announced public offering of an aggregate of 1,290,322 shares of its common stock, Series A-1 warrants to purchase up to 1,290,322 shares of common stock and Series A-2 warrants to purchase 1,290,322 shares of common stock, at a combined public offering price of $7.75 per share and accompanying warrants.

Metacrine, Inc. and Equillium, Inc. announced the mutual termination of their previously announced definitive merger agreement.

Soligenix, Inc. announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.001 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 p.m. Eastern Standard Time on January 3, 2023.

Gilead Sciences, Inc. announced that its executives will be speaking at the following investor conference: J.P. Morgan Healthcare Conference on Monday, January 9, 2023 beginning at 10:30 a.m. Pacific Time.

Equillium, Inc. and Metacrine, Inc. announced the mutual termination of their previously announced definitive merger agreement.

Terns Pharmaceuticals, Inc. announced the closing of its previously announced underwritten public offering of 11,902,500 shares of its common stock, including 1,552,500 shares sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares, at a public offering price of $7.25 per share, before underwriting discounts and commissions.